[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-coagulation-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-coagulation-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,53,82,117,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":19,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":36,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100264360","investigation-of-the-genetics-of-hematologic-diseases-100264360",false,"NCT02720679","Investigation of the Genetics of Hematologic Diseases","Inclusion Criteria:\n\n* An individual (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder, MDS or MPN.\n* A biologically-related individual to the identified proband to include: first, second or third degree relatives.\n\nExclusion Criteria:\n\n* None","ALL",{"count":17,"type":18},1716,"ESTIMATED","10 Years","OBSERVATIONAL","The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment of blood diseases. This is not a therapeutic or diagnostic protocol for clinical purposes. Blood, bone marrow, hair follicles, nail clippings, urine, saliva and buccal swabs, left over tissue, as well as health information will be used to study and learn about blood diseases by using genetic and\u002For genomic research. In general, genetic research studies specific genes of an individual; genomic research studies the complete genetic makeup of an individual.\n\nIt is not known why many people have blood diseases, because not all genes causing these diseases have been found. It is also not known why some people with the same disease are sicker than others, but this may be related to their genes. By studying the genomes in individuals with blood diseases and their family members, the investigators hope to learn more about how diseases develop and respond to treatment which may provide new and better ways to diagnose and treat blood diseases.\n\nPrimary Objective:\n\n* Establish a repository of DNA and cryopreserved blood cells with linked clinical information from individuals with non-malignant blood diseases and biologically-related family members, in conjunction with the existing St. Jude biorepository, to conduct genomic and functional studies to facilitate secondary objectives.\n\nSecondary Objectives:\n\n* Utilize next generation genomic sequencing technologies to Identify novel genetic alternations that associate with disease status in individuals with unexplained non-malignant blood diseases.\n* Use genomic approaches to identify modifier genes in individuals with defined monogenic non-malignant blood diseases.\n* Use genomic approaches to identify genetic variants associated with treatment outcomes and toxicities for individuals with non-malignant blood disease.\n* Use single cell genomics, transcriptomics, proteomics and metabolomics to investigate biomarkers for disease progression, sickle cell disease (SCD) pain events and the long-term cellular and molecular effects of hydroxyurea therapy.\n* Using longitudinal assessment of clinical and genetic, study the long-term outcomes and evolving genetic changes in non-malignant blood diseases.\n\nExploratory Objectives\n\n* Determine whether analysis of select patient-derived bone marrow hematopoietic progenitor\u002Fstem (HSPC) cells or induced pluripotent stem (iPS) cells can recapitulate genotype-phenotype relationships and provide insight into disease mechanisms.\n* Determine whether analysis of circulating mature blood cells and their progenitors from selected patients with suspected or proven genetic hematological disorders can recapitulate genotype-phenotype relationships and provide insight into disease mechanisms.",[23,24,25,26,27,28,29,30,31,32,33,34,35],"Bone Marrow Failure Syndromes","Erythrocyte Disorder","Leukocyte Disorder","Hemostasis","Blood Coagulation Disorder","Sickle Cell Disease","Dyskeratosis Congenita","Diamond-Blackfan Anemia","Congenital Thrombocytopenia","Severe Congenital Neutropenia","Fanconi Anemia","Myelodysplastic Syndromes","Myeloproliferative Diseases",[37,38,39],"Genetics","Whole genome sequencing","Pediatrics and hematology","RECRUITING","2026-06-05",{"date":43,"type":44},"2026-06-09","ACTUAL",{"date":46,"type":44},"2016-06-17",{"date":48,"type":18},"2050-07",{"name":50,"class":51},"St. Jude Children's Research Hospital","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":15,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":52},"100605575","comparative-study-of-tranexamic-acid-dosing-in-cardiac-surgery-100605575","NCT07164300","Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery","Comparative Study of Tranexamic Acid Dosage Regimens in Patients Undergoing Cardiac Surgery Under Cardiopulmonary Bypass","Inclusion Criteria:\n\n* Patients undergoing elective cardiac surgery using cardiopulmonary bypass\n* Patients to have discontinued anticoagulant and antiplatelet therapy preoperatively according to guidelines.\n\nExclusion Criteria:\n\n* Age below 18 years\n* Patient refusal\n* Pregnancy\n* End-stage renal disease\n* History of epilepsy,\n* Cardiac surgery without the use of cardiopulmonary bypass (off-pump)\n* Emergency operations\n* Known allergy to the administered agents.","18 Years","99 Years",{"count":63,"type":18},150,"INTERVENTIONAL",[66],"NA","Tranexamic axid is routinely used as an antifibrinolytic agent in cardiac surgery to reduce the risk of blood loss and transfusion. However, there is no consensus regarding the dosage regimen of tranexamic acid that should be administered. The purpose of this study is to compare different dosages of tranexamic acid in cardiac surgery using cardiopulmonary bypass regarding the duration of inhibition of fibrinolysis as measured by the ClotPro test.\n\nBlood samples will be taken from the arterial line placed in the patient at specified time points in order to perform viscoelastic tests (ClotPro, TPA test), to detect successful inhibition of fibrinolysis and to measure tranexamic acid levels in the patient's blood. In case the action of tranexamic acid stops early postoperatively an additional dose of the medication will be administered to the patient.",[27,69,70,71,72],"Postoperative Blood Loss","Adverse Drug Event","Fibrinolysis; Hemorrhage","Tranexamic Acid Adverse Reaction","2025-09-05",{"date":75,"type":44},"2025-09-10",{"date":77,"type":44},"2024-05-14",{"date":79,"type":18},"2027-12-15",{"name":81,"class":51},"University of Ioannina",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":90,"targetDuration":92,"studyType":20,"phases":4,"briefSummary":93,"conditions":94,"keywords":102,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":52},"100547068","transfusion-surveillance-in-anaesthesia-100547068","NCT06403163","Transfusion Surveillance in Anaesthesia","Biological Transfusion Efficiency Registry Transfusion Surveillance in Anaesthesia","STAR","Inclusion Criteria:\n\n* all patients who have received an hemostasis product\n\nExclusion Criteria:\n\n* patient who refused to consent to data analysis and study participation",{"count":91,"type":18},50000,"2 Weeks","the aim of this register is to collect exhaustively the different data available surrounding a transfusion act in the context of an active haemorrhage. The aim is to allow different modelling and analysis related to emergency transfusion.",[95,96,97,98,99,100,27,101],"Transfusion Reaction","Transfusion Related Complication","Anesthesia","Anesthesia; Shock","Side Effect","Fresh Blood Stool","Blood Loss",[103,104,105,106,107],"transfusion","monitoring","emergency situation","shock","fresh frozen plasma","2025-08-25",{"date":110,"type":44},"2025-09-02",{"date":112,"type":44},"2022-09-01",{"date":114,"type":18},"2030-12-31",{"name":116,"class":51},"Erasme University Hospital",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":125,"sex":15,"minAge":60,"maxAge":126,"enrollmentInfo":127,"targetDuration":129,"studyType":20,"phases":4,"briefSummary":130,"conditions":131,"keywords":136,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":52},"100305417","dynamics-of-platelet-activation-in-patients-with-ventricular-assist-device-vad-100305417","NCT03255928","Dynamics of Platelet Activation in Patients With Ventricular Assist Device (VAD)","Analysis of the Platelet Activity State in Patients Implanted With Ventricular Assist Device (VAD)","PASVAD","Inclusion Criteria:\n\n* All consenting patients candidates for short-term (Impella, ECMO) or durable (LVAD) mechanical circulatory support device implantation\n* All consenting patients that are implanted with short-term (Impella, ECMO) or durable (LVAD) mechanical circulatory support device\n\nExclusion Criteria:\n\n\\- Patients \\\u003C 18-years old",true,"75 Years",{"count":128,"type":18},60,"2 Years","Consenting patients with end-stage heart failure that are implanted with\u002Fcandidates for implant of a short-term\u002Fdurable mechanical circulatory support device (e.g.: percutaneous microaxial pumps (Impella), extracorporeal membrane oxygenator (ECMO), Ventricular Assist Device (VAD) will be enrolled in the study.\n\nAim of the study is to evaluate the patients' haemostatic and coagulation profile, how it interacts with the support device as well as the effect of antithrombotic drugs. From these data, it will be possible to derive the mechanisms triggering post-implant thromboembolic\u002Fhemorrhagic complications and to identify potential therapeutic targets.",[132,27,133,134,135],"Thrombosis","Platelet Thrombus","Platelet Dysfunction Due to Aspirin","Failure;Ventricular",[137,138,132,139,140,141],"Platelet activation","Ventricular Assist Device","Bleeding","Antithrombotic Pharmacological Therapy","Mechanical Circulatory Support","2025-05-12",{"date":144,"type":44},"2025-05-15",{"date":146,"type":44},"2017-06-29",{"date":148,"type":18},"2026-12-31",{"name":150,"class":51},"Scientific Institute San Raffaele",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":15,"minAge":60,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":52},"100560854","evaluation-of-clinical-ranges-of-whole-blood-clotting-times-of-patients-on-anticoagulants-100560854","NCT06582563","Evaluation of Clinical Ranges of Whole Blood Clotting Times of Patients on Anticoagulants","Study for Evaluation of Clinical Ranges of Whole Blood Clotting Times","Inclusion Criteria:\n\n* In general, study participants must:\n\n  1. Be informed of the nature of the study and provide written informed consent before any study-specific procedures are performed.\n  2. Be 18- to 80-years-of-age, inclusive, at time of consent.\n  3. Have suitable venous access for at least a single venipuncture.\n  4. Eligible patients on anticoagulants must have taken their prescribed anticoagulant regularly at least for one month prior to study participation for inclusion\n\nExclusion Criteria:\n\n* Eligible patients on anticoagulants must not:\n\n  1. Other than the condition for which a DOAC was prescribed , have a personal or family history of clotting disorder or hematologic abnormality, such as excessive bleeding, joint hematoma, thrombovascular disease, thrombocytopenia, or any chronic condition requiring treatment with transfusions.\n  2. Have a BMI\\> 40 or weight \\> 120kg.\n  3. Suffer from renal or hepatic insufficiency.\n  4. Suffer from any pathology that would contra-indicate in general DOAC medication.\n  5. Have a history of unexplained syncope.\n  6. Have a history within 6 months prior to Screening of peptic ulcer or gastrointestinal bleeding (including hematemesis, melena, or rectal bleeding).\n  7. Consume more than 5 cigarettes per day.\n  8. If female, have a history of excessive or dysfunctional uterine bleeding (unless the subject had a subsequent hysterectomy).\n  9. If female is pregnant, breastfeeding, or planning to become pregnant during study","80 Years",{"count":160,"type":18},120,"Whole blood clotting time measurements are to collect the clotting time ranges for DOAC-anticoagulated patients and assess their correlation with plasma drug levels (via anti-FXa assay).",[27],"NOT_YET_RECRUITING","2024-10-03",{"date":166,"type":44},"2024-10-08",{"date":168,"type":18},"2025-03-01",{"date":170,"type":18},"2025-08-30",{"name":172,"class":173},"Perosphere Technologies Inc.","INDUSTRY"]